Pyridorin™

NephroGenex acquired commercial rights to Pyridorin™ and is currently investigating the safety and efficacy of Pyridorin™ therapy for kidney diseases in which pathogenic oxidative chemistries are an established causative factor. These include diabetic nephropathy and acute renal failure.

Diabetic Nephropathy

Pyridorin™ targets a broad range of pathogenic oxidative chemistries, including advanced glycation end-products, toxic carbonyls, and reactive oxygen species that develop in patients with diabetes and are considered a principal causative factor in the development of diabetic microvascular disease. Hyperglycemia-induced microvascular disease is the fundamental cause of diabetic complications, including nephropathy, retinopathy, and neuropathy.

Pyridorin™ has been evaluated in three Phase 2 clinical trials and in all three trials has demonstrated a significant treatment effect in retarding the progression of diabetic nephropathy. NephroGenex is continuing the clinical study of Pyridorin™ for diabetic overt nephropathy in a Phase 3 Subpart H program that uses a novel surrogate endpoint that provides for an accelerated regulatory pathway to approval.

Other Indications

NephroGenex is also studying the application of Pyridorin™ to specific types of acute renal failure in which pathogenic oxidative chemistries have been identified as likely causative factors in the onset and progression of this condition. These include contrast-dye-induced acute renal failure and ischemia-reperfusion acute renal injury, which can arise in cardiac and vascular surgeries.